Prescription Screening for Drug Interaction Identification in Patients with Diabetes Mellitus and Hyperuricemia from October 2023 to March 2024 at Advent Hospital
Article Sidebar
Main Article Content
Page: 1142-1151
Abstract
Background: Diabetes mellitus (DM) and hyperuricemia are frequently encountered comorbidities in clinical practice with increasing prevalence. Long-term pharmacological therapy for these conditions carries the potential for drug interactions and other drug-related problems. Prescription completeness evaluation and drug interaction identification are necessary to ensure therapeutic safety and efficacy. Objectives: This study aimed to identify medications prescribed for patients with DM and hyperuricemia, evaluate potential drug interactions, and assess prescription completeness based on administrative standards according to Indonesian Ministry of Health Regulation No. 72 of 2016. Methods: This retrospective descriptive study with a cross-sectional design analyzed 50 outpatient prescriptions at Advent Hospital Medan from October 2023 to March 2024. The analysis covered administrative, pharmaceutical, and clinical aspects. Drug interactions were identified using Drugs.com with classification as major, moderate, and minor. Results: The most frequently prescribed antidiabetic drugs were metformin (82%), glimepiride (76%), and acarbose (64%), while for hyperuricemia they were allopurinol (88%) and meloxicam (72%). Ten drug interactions were identified, consisting of 8 moderate (80%), 1 major (10%), and 1 minor (10%). Administrative evaluation showed 92% completeness for mandatory components, but patient weight (48%), physician address (64%), and physician phone number (56%) were frequently omitted. Conclusion: The study revealed a significant prevalence of moderate drug interactions between antidiabetic drugs and non-steroidal anti-inflammatory drugs (NSAIDs). Optimization of prescription screening systems and completion of patient clinical data are required to enhance therapy safety.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010. https://doi.org/10.1016/j.diabres.2009.10.007. DOI: https://doi.org/10.1016/j.diabres.2009.10.007
IDF. International Diabetes Federation. vol. 102. 10th editi. USA: IDF; 2021. https://doi.org/10.1016/j.diabres.2013.10.013. DOI: https://doi.org/10.1016/j.diabres.2013.10.013
Yuswar MA, Nugraha F. Gambaran Kualitas Hidup Pasien Diabetes Melitus Menggunakan Instrumen DQLCTQ Studi Kasus: Puskesmas X Kota Pontianak. Indones J Pharm Educ 2023;3. DOI: https://doi.org/10.37311/ijpe.v3i3.19362
Rahman AO, Ayu NN, Purwakanthi A. Pemeriksaan Kadar Gula Darah Dan Kadar Asam Urat Pada Masyarakat di Bundaran Tugu Keris Siginjai Jambi Sebagai Skrining Awal Penyakit Diabetes Mellitus Dan Hiperurisemia. Med Dedication J Pengabdi Kpd Masy FKIK UNJA 2019;2:45–8.
Richette P, Doherty M, Pascual E, Барскова ВГ, Becce F, Castañeda-Sanabria J, et al. 2016 Updated EULAR Evidence-Based Recommendations for the Management of Gout. Ann Rheum Dis 2017;76:29–42. https://doi.org/10.1136/annrheumdis-2016-209707. DOI: https://doi.org/10.1136/annrheumdis-2016-209707
Becker MA, MacDonald PA, Hunt B, Jackson RL. Diabetes and Gout: Efficacy and Safety of Febuxostat and Allopurinol. Diabetes Obes Metab 2013;15:1049–55. https://doi.org/10.1111/dom.12135. DOI: https://doi.org/10.1111/dom.12135
Tung Y, Lee S, Tsai W, Lin G, Chang H-W, Tu H. Association Between Gout and Incident Type 2 Diabetes Mellitus: A Retrospective Cohort Study. Am J Med 2016;129:1219.e17-1219.e25. https://doi.org/10.1016/j.amjmed.2016.06.041. DOI: https://doi.org/10.1016/j.amjmed.2016.06.041
Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, et al. Sex Differences in Gout Characteristics: Tailoring Care for Women and Men. BMC Musculoskelet Disord 2017;18. https://doi.org/10.1186/s12891-017-1465-9. DOI: https://doi.org/10.1186/s12891-017-1465-9
Wijnands JMA, Durme CMPG van, Driessen JHM, Boonen A, Klop C, Leufkens B, et al. Individuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout but This Is Not Due to Diabetes. Medicine (Baltimore) 2015;94:e1358. https://doi.org/10.1097/md.0000000000001358. DOI: https://doi.org/10.1097/MD.0000000000001358
Oh Y-J, Lee YJ, Lee E, Park B, Kwon J, Heo J, et al. Cancer Risk in Korean Patients With Gout. Korean J Intern Med 2022;37:460–7. https://doi.org/10.3904/kjim.2020.259. DOI: https://doi.org/10.3904/kjim.2020.259
Rasmussen C, Larsen JW, Holm PS, Nielsen GL. Gout: An Overlooked Disease in Patients With Diabetes? A Danish Prospective Cohort Study With 2 Years of Follow-Up. Clin Diabetes 2025. https://doi.org/10.2337/cd24-0082. DOI: https://doi.org/10.2337/cd24-0082
Kementrian Kesehatan Republik Indonesia. Laporan Nasional Riskesdas 2018. Jakarta: 2018.
Poluan OA, Wiyono WI, Yamlean PVY. Identifikasi Potensi Interaksi Obat Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap Di Rumah Sakit Gunung Maria Tomohon Periode Januari sampai Mei 2018. Pharmacon 2020;9:38–46. DOI: https://doi.org/10.35799/pha.9.2020.27408
Aztriana A, Mumtihanah A, Kadir MA. Kesesuaian Pengkajian Resep Racikan Pediatri di RSUD Siwa. Makassar Pharm Sci J 2023;1:19–30. DOI: https://doi.org/10.33096/mpsj.v1i1.18
Drugs.com. Prescription Drug Information, Interactions and Side Effects. DrugsCom 2025. https://www.drugs.com/drug-interactions/diclofenac-with-metformin-869-0-1573-0.html.
Rahman H, Octavia TA. Kajian Interaksi Obat Metformin pada Pasien Diabetes Mellitus. J Farmasetis 2019;8:55–8. DOI: https://doi.org/10.32583/farmasetis.v8i2.592
Aeni SN, Sukandar EY, Hermanto F. Kajian Interaksi Obat Pasien Diabetes di Beberapa Rumah Sakit di Indonesia. J Buana Farma 2024;4:204–18. DOI: https://doi.org/10.36805/jbf.v4i3.1123
Awaliya EW, Mayasari S, Cendikiawan KA. Potential Hypoglycemia in Patients With Type 2 Diabetes Mellitus Due to Drug Interactions in Citra Husada Hospital n.d.
Radiah N, Pratama IA, Pahmi K. Studi Penggunaan NSAID (Nonsteroidal Anti Inflamantory Drugs) Pasien Osteoarthritis Usia Lanjut di Rumah Sakit X Sumbawa Barat. J Syifa Sci Clin Res 2023;5:424–8. DOI: https://doi.org/10.37311/jsscr.v5i3.23723
Rahmawaty A, Hidayah PH. Hubungan Drug Related Problems (DRPs) Kategori Interaksi Obat pada Penggunaan Obat Pasien Diabetes Mellitus Tipe 2. Cendekia J Pharm 2020;4:80–8. DOI: https://doi.org/10.31596/cjp.v4i1.76
Chakraborty C, Hsu MJ, Agoramoorthy G. Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with sitagliptin and inhibitor diprotin-A. Cell Biochem Biophys 2014;70:907–22. DOI: https://doi.org/10.1007/s12013-014-9998-0
Chakraborty D. Pharmacodynamics: Mechanism of Drug Action. Essentials Pharmacodyn. Drug Action, Springer; 2024, p. 5–39. DOI: https://doi.org/10.1007/978-981-97-2776-6_2
Ussa RE. Hubungan Interaksi Antar Obat Terhadap Kadar Gula Darah Pada Pasien Diabetes Rawat Inap Di Rumah Sakit Islam Sultan Agung Semarang Periode 2020 2021.
Sari IN. Evaluasi drug related problems obat antidiabetes pada pasien geriatri dengan diabetes melitus tipe 2 di ruang rawat inap rumah sakit umum Pelabuhan periode Januari-Juni 2014 2015.
Setyoningsih H, Zaini F. Hubungan Interaksi Obat Terhadap Efektivitas Obat Antihipertensi di RSUD dr. R. Soetrasno Rembang. Cendekia J Pharm 2022;6:76–88. DOI: https://doi.org/10.31596/cjp.v6i1.186
Setyoningsih H, Yudanti GP, Ismah K, Handayani Y, Nida HN. Evaluasi Penggunaan Antibiotik Pada Pasien Diabetes Mellitus Dengan Ulkus Diabetikum Bedasarkan Metode Gyssens Di Rumah Sakit Islam Kudus. Cendekia J Pharm 2022;6:257–69. DOI: https://doi.org/10.31596/cjp.v6i2.210
Permadi YW, Riadi I, Rahmatullah S. Analisis Polifarmasi Terhadap Interaksi Obat Di Rumah Sakit Umum Kota Pekalongan. Lamda J Ilm Pendidik MIPA Dan Apl 2025;5:69–82. DOI: https://doi.org/10.58218/lambda.v5i1.1200